Your browser doesn't support javascript.
loading
Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein.
Pinho, Raquel; Paiva, Isabel; Jercic, Kristina Gotovac; Fonseca-Ornelas, Luis; Gerhardt, Ellen; Fahlbusch, Christiane; Garcia-Esparcia, Paula; Kerimoglu, Cemil; Pavlou, Maria A S; Villar-Piqué, Anna; Szego, Éva; Lopes da Fonseca, Tomás; Odoardi, Francesca; Soeroes, Szabolcs; Rego, Ana Cristina; Fischle, Wolfgang; Schwamborn, Jens C; Meyer, Thomas; Kügler, Sebastian; Ferrer, Isidre; Attems, Johannes; Fischer, André; Becker, Stefan; Zweckstetter, Markus; Borovecki, Fran; Outeiro, Tiago F.
Afiliação
  • Pinho R; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Göttingen, Göttingen, Germany.
  • Paiva I; Faculty of Medicine, University of Porto, Porto, Portugal.
  • Jercic KG; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Göttingen, Göttingen, Germany.
  • Fonseca-Ornelas L; Department for Functional Genomics, Center for Translational and Clinical Research, University Hospital Center Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Gerhardt E; Max Planck Institute for Biophysical Chemistry, Göttingen, Germany.
  • Fahlbusch C; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Göttingen, Göttingen, Germany.
  • Garcia-Esparcia P; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Göttingen, Göttingen, Germany.
  • Kerimoglu C; Institute of Neuropathology, Bellvitge University Hospital, University of Barcelona, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat; Biomedical Research Center of Neurodegenerative Diseases, Barcelona, Spain.
  • Pavlou MAS; Department for Psychiatry and Psychotherapy, University Medical Center, Göttingen, Germany.
  • Villar-Piqué A; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Göttingen, Göttingen, Germany.
  • Szego É; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Göttingen, Göttingen, Germany.
  • Lopes da Fonseca T; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Göttingen, Göttingen, Germany.
  • Odoardi F; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Göttingen, Göttingen, Germany.
  • Soeroes S; Institute of Neuroimmunology and Institute for Multiple Sclerosis Research, University Medical Centre Göttingen, Göttingen, Germany.
  • Rego AC; Max Planck Institute for Biophysical Chemistry, Laboratory of Chromatin Biochemistry, Göttingen, Germany.
  • Fischle W; Oxford Nanopore Technologies LTD, Oxford, United Kingdom.
  • Schwamborn JC; Center for Neuroscience and Cell Biology and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
  • Meyer T; Max Planck Institute for Biophysical Chemistry, Laboratory of Chromatin Biochemistry, Göttingen, Germany.
  • Kügler S; King Abdullah University of Science and Technology, Environmental Epigenetics Program, Thuwal, Saudi Arabia.
  • Ferrer I; Development and Cellular Biology, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Attems J; Klinik für Psychosomatische Medizin und Psychotherapie, Universitätsmedizin Göttingen, Göttingen, Germany.
  • Fischer A; Department of Neurology, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Göttingen, Göttingen, Germany.
  • Becker S; Institute of Neuropathology, Bellvitge University Hospital, University of Barcelona, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat; Biomedical Research Center of Neurodegenerative Diseases, Barcelona, Spain.
  • Zweckstetter M; Institute of Neuroscience, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, United Kingdom.
  • Borovecki F; Department for Psychiatry and Psychotherapy, University Medical Center, Göttingen, Germany.
  • Outeiro TF; Department of Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen Germany.
Hum Mol Genet ; 28(1): 31-50, 2019 01 01.
Article em En | MEDLINE | ID: mdl-30219847
ABSTRACT
Alpha-synuclein (aSyn) is a central player in Parkinson's disease (PD) but the precise molecular mechanisms underlying its pathogenicity remain unclear. It has recently been suggested that nuclear aSyn may modulate gene expression, possibly via interactions with DNA. However, the biological behavior of aSyn in the nucleus and the factors affecting its transcriptional role are not known. Here, we investigated the mechanisms underlying aSyn-mediated transcription deregulation by assessing its effects in the nucleus and the impact of phosphorylation in these dynamics. We found that aSyn induced severe transcriptional deregulation, including the downregulation of important cell cycle-related genes. Importantly, transcriptional deregulation was concomitant with reduced binding of aSyn to DNA. By forcing the nuclear presence of aSyn in the nucleus (aSyn-NLS), we found the accumulation of high molecular weight aSyn species altered gene expression and reduced toxicity when compared with the wild-type or exclusively cytosolic protein. Interestingly, nuclear localization of aSyn, and the effect on gene expression and cytotoxicity, was also modulated by phosphorylation on serine 129. Thus, we hypothesize that the role of aSyn on gene expression and, ultimately, toxicity, may be modulated by the phosphorylation status and nuclear presence of different aSyn species. Our findings shed new light onto the subcellular dynamics of aSyn and unveil an intricate interplay between subcellular location, phosphorylation and toxicity, opening novel avenues for the design of future strategies for therapeutic intervention in PD and other synucleinopathies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Alfa-Sinucleína Limite: Animals / Humans Idioma: En Revista: Hum Mol Genet Assunto da revista: BIOLOGIA MOLECULAR / GENETICA MEDICA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Alfa-Sinucleína Limite: Animals / Humans Idioma: En Revista: Hum Mol Genet Assunto da revista: BIOLOGIA MOLECULAR / GENETICA MEDICA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha